共 41 条
- [31] A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6).JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Waldron, John N.Parulekar, WendyO'Sullivan, BrianChen, Bingshu E.Montenegro, AlexanderNabid, AbdenourWinquist, EricWright, Jim R.Hay, JohnRingash, JolieMartino, RosemaryJohnson, AnaLiu, GeoffreyBreen, StephenGilbert, Ralph WilliamShenouda, GeorgeSiu, Lillian L.
- [32] Re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol 2020;77:260-8EUROPEAN UROLOGY, 2020, 77 (06) : E154 - E155Liu, WeiLiu, XiaopingLi, Shen
- [33] Sequential BCG and mitomycin intravesical therapy versus BCG alone for high-risk non-muscle invasive bladder cancer (NMIBC): pilot study and proposal for a 2-stage randomized phase III trialBJU INTERNATIONAL, 2011, 107 : 25 - 26Hayne, D.Stockler, M.Ives, A.Houghton, B.Braganza, P.Chalasani, V.Patel, M.
- [34] Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS"EUROPEAN UROLOGY, 2020, 78 (05) : 690 - 698Grimm, Marc-Olivervan der Heijden, Antoine G.Colombel, MarcMuilwijk, TimMartinez-Pineiro, LuisBabjuk, Marko M.Turkeri, Levent N.Palou, JoanPatel, AnupBjartell, Anders S.Caris, ChristienSchipper, Raymond G.Witjes, Wim P. J.Horstmann, JoergMachtens, StefanMumperow, EberhardAl Ghazal, AndreasPulte, ThomasStephan-Odenthal, MichaelGakis, GeorgiosKramer, MarioZaak, DirkSchmitz-Draeger, BerndSchreier, HolgerLehmann, JanWerner, TorstenKlier, JoergMarin, JanRulf, WolfgangHellmis, EvaSchneider, AndreasSpiegelhalderWirth, ManfredKlotz, TheodorSuttmann, HenrikSiebels, MichaelRodemer, GerdRudolph, RobertZillmann, Rogerde Bruin, M.Bos, S.van Moorselaar, R.de Reijke, T.Boormans, J.Wijsman, B.van Melick, H. H. E.van Boven, E.Meijer, R. P.van der Heijden, A. G.Vergunst, H.
- [35] Long-term Toxicity Report From a Phase II Study of Accelerated Twice-Daily (BD) versus High Dose Once-Daily (OD) Thoracic Radiotherapy (RT) With Concurrent Chemotherapy for Limited-Stage Small Cell Lung Cancer (LS-SCLC)INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S589 - S589Faivre-Finn, C.Blackball, F.Ashcroft, L.Thatcher, N.Taylor, P.Lorigan, P.
- [36] Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel plus Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily IrradiationEUROPEAN UROLOGY ONCOLOGY, 2024, 7 (01): : 83 - 90Dahl, Douglas M.Karrison, Theodore G.Michaelson, M. DrorPham, Huong T.Wu, Chin-LeeSwanson, Gregory P.Shipley, William U.Vuky, JacquelineLee, R. JeffreyZietman, Anthony L.Souhami, LuisChang, Brian K.Deming, Richard L.Ellerton, John A.Sandler, Howard M.Rodgers, Joseph P.Feng, Felix Y.Efstathiou, Jason A.
- [37] CA184-043: A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following a single dose of radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D)JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Drake, Charles G.Scher, Howard I.Bossi, Albertovan den Eertwegh, Alfons J. M.McHenry, BrentFitzmaurice, Thomas F.Cuillerot, Jean-MarieChin, Kevin M.Gagnier, PaulFizazi, KarimGerritsen, Winald R.
- [38] LONG-TERM OUTCOMES FROM INTERGROUP NCCTG 86-72-51 (ALLIANCE): FINAL REPORT OF A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF HIGH DOSE VERSUS LOW DOSE RADIATION IN ADULT SUPRATENTORIAL LOW-GRADE GLIOMANEURO-ONCOLOGY, 2019, 21 : 13 - 14Breen, WilliamAnderson, S. KeithCarrero, XiomaraBrown, PaulBallman, KarlaO'Neill, BrianCurran, WalterAbrams, RossLaack, NadiaLevitt, RalphGalanis, EvanthiaBuckner, JanShaw, Edward
- [39] PHASE III MULTI-INSTITUTIONAL TRIAL OF ADJUVANT CHEMOTHERAPY WITH PACLITAXEL, ESTRAMUSTINE, AND ORAL ETOPOSIDE COMBINED WITH LONG-TERM ANDROGEN SUPPRESSION THERAPY AND RADIOTHERAPY VERSUS LONG-TERM ANDROGEN SUPPRESSION PLUS RADIOTHERAPY ALONE FOR HIGH-RISK PROSTATE CANCER: PRELIMINARY TOXICITY ANALYSIS OF RTOG 99-02INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (03): : 672 - 678Rosenthal, Seth A.Bae, KyoungwhaPienta, Kenneth J.Sobczak, Mark L.Asbell, Sucha O.Rajan, RaghuKerlin, Kevin J.Michalski, Jeff M.Sandler, Howard M.
- [40] Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol 2020;77:260-8EUROPEAN UROLOGY, 2020, 77 (06) : E156 - E157Huddart, RobertHall, EmmaLewis, RebeccaPorta, NuriaHussain, Syed A.James, Nicholas D.